Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment
Introduction: SCLC is an aggressive malignancy with poor outcome. Most patients have disease recurrence despite treatments with multiple modalities. Subtyping of SCLC has been proposed recently, and novel agents targeting specific subtypes are actively being investigated. In this study, we evaluated...
Main Authors: | Ying-Chun Lo, MD, PhD, Joel Rivera-Concepcion, MD, George Vasmatzis, PhD, Marie-Christine Aubry, MD, Konstantinos Leventakos, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-09-01
|
Series: | JTO Clinical and Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364323001042 |
Similar Items
-
Sputum microbiota and inflammatory subtypes in asthma, COPD, and its overlap
by: Chie Morimoto, MD, PhD, et al.
Published: (2024-02-01) -
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyCapsule Summary
by: Xue Bai, MD, et al.
Published: (2024-06-01) -
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
by: Hiroaki Kanemura, MD, MPH, et al.
Published: (2022-08-01) -
Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-07-01) -
De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
by: Takanori Ito, MD, et al.
Published: (2023-05-01)